FDA Gives Orca Bio a Major Win in Stem Cell Blood Cancer Cell Therapy
Orca Bio’s FDA approval marks a major step forward for engineered cell therapy in blood cancers, especially because Orca-T is designed to reduce the dangerous complications that can follow traditional donor stem cell transplants. The green light gives the field a concrete example of how precision cell therapy can improve an established treatment rather than replace it outright.